Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial

Steven G. Potkin, Larry Alphs, Chuanchieh Hsu, K. Ranga Rama Krishnan, Ravi Anand, Frederick K. Young, Herbert Meltzer, Alan Green, Saide Altinsan, Siemion Altman, Likiana Avigo, Richard Balon, Vanda Benešová, Luis Bengochea, Istvan Bitter, Elisabeth Bokowska, Bernardo Carpiniello, Daniel Casey, Giovanni Cassano, James ChouGuy Chouinard, Libor Chvila, Jean Dalery, Pedro Delgado, Liliana Dell'Osso, Carl Eisdorfer, Robin A. Emsley, T. A. Fahy, Vera Folnegovic, Sophie Frangou, Pedro Gargoloff, Alberto Giannelli, Ira Glick, Richard Greenberg, George T. Grossberg, Doris Gundersen, Hannale Heila, George Hsu, Naveed Iqbal, M. Miro Jakovljevic, Richard C. Josiassen, Akos Kassaifarkas, Rob Kerwin, Frederic Khidichian, Mary Ann Knesevich, Jack Krasuski, Vinod Kumar, Veronica Walters Larach, Michael Lesem, Shon Lewis, Pierre Michel Llorca, H. Edward Logue, Stephen Martin, Muriel Maurel-Raymondet, Laszlo Mod, Eva Morik, Carlos Morra, Ann Mortimer, Mojtaba Noursalehi, Gyorgy Ostorharics-Horvath, Ivo Paclt, Jorg J. Pahl, Jeffrey Lee Peters, Rosario Pioli, Michael G. Plopper, Thomas Posever, Mark Rapaport, Delbert Robinson, Carlo Andrea Robotti, Frederic Rouillon, David Sack, Isaac Sakinsofsky, Phillip Seibel, George Simpson, Nancy Temkin, Oladapo Tomori, Santha Vaidain, Zdeòka Vyhnándová, Daniel Zimbroff, Marie Agathe Zimmerman

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Abstract

Background: Enhanced ability to reliably identify risk factors for suicidal behavior permits more focused decisions concerning treatment interventions and support services, with potential reduction in lives lost to suicide. Methods: This study followed 980 patients at high risk for suicide in a multicenter prospective study for 2 years after randomization to clozapine or olanzapine. A priori predictors related to diagnosis, treatment resistance, and clinical constructs of disease symptoms were evaluated as possible predictors of subsequent suicide-related events. Results: Ten baseline univariate predictors were identified. Historical predictors were diagnosis of schizoaffective disorder, history or current use at baseline of alcohol or substance abuse, cigarette smoking, number of lifetime suicide attempts, and the number of hospitalizations in the previous 36 months to prevent suicide. Predictive clinical features included greater baseline scores on the InterSePT scale for suicidal thinking, the Covi Anxiety Scale, the Calgary Depression Scale (CDS), and severity of Parkinsonism. Subsequent multivariate analysis revealed the number of hospitalizations in the previous 36 months, baseline CDS, severity of Parkinson's, history of substance abuse, and lifetime suicide attempts. Clozapine, in general, was more effective than olanzapine in decreasing the risk of suicidality, regardless of risk factors present. Conclusions: This is the first prospective analysis of predictors of suicide risk in a large schizophrenic and schizoaffective population judged to be at high risk for suicide. Assessment of these risk factors may aid clinicians in evaluating risk for suicidal behaviors so that appropriate interventions can be made.

Original languageEnglish (US)
Pages (from-to)444-452
Number of pages9
JournalBiological Psychiatry
Volume54
Issue number4
DOIs
StatePublished - Aug 15 2003

Keywords

  • Clozapine
  • Olanzapine
  • Risk factors
  • Schizoaffective disorder
  • Schizophrenia
  • Suicidality
  • Suicide

ASJC Scopus subject areas

  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial'. Together they form a unique fingerprint.

Cite this